PDM
CELG

Penn Davis McFarland’s Celgene Corp CELG Stock Holding History

Penn Davis McFarland’s Portfolio CELG Stock Details CELG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-210,502
Closed -$20.9M – 53
2019
Q3 		$20.9M Sell
210,502
-1,849
-0.9% -$176K 6.54% 6
2019
Q2 		$19.6M Sell
212,351
-62
-0% -$5.89K 6.64% 5
2019
Q1 		$20M Sell
212,413
-3,784
-2% -$331K 6.93% 5
2018
Q4 		$13.9M Buy
216,197
+36,595
+20% +$2.7M 5.38% 7
2018
Q3 		$16.1M Buy
179,602
+3,711
+2% +$328K 4.63% 9
2018
Q2 		$14M Buy
175,891
+143
+0.1% +$11.9K 4.3% 9
2018
Q1 		$15.7M Buy
175,748
+6,222
+4% +$597K 4.79% 7
2017
Q4 		$17.7M Buy
169,526
+101,686
+150% +$11.5M 5.18% 7
2017
Q3 		$9.89M Sell
67,840
-2,301
-3% -$313K 3.06% 16
2017
Q2 		$9.11M Buy
70,141
+425
+0.6% +$52.1K 2.7% 19
2017
Q1 		$8.68M Buy
+69,716
New +$8.34M 2.53% 20

Other funds holding CELG

FP
Factorial Partners Mt. Kisco, New York $138M AUM 25.59% 1-Year Est. Return
HCM
Howard Capital Management Roswell, Georgia $6.11B AUM 33.56% 1-Year Est. Return
PCMC
Private Capital Management (Colorado) Denver, Colorado $501M AUM 17.09% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $420M AUM 14.29% 1-Year Est. Return

Penn Davis McFarland's CELG Position: Q4 2019 in Review

Penn Davis McFarland sold out of Celgene Corp (CELG) in Q4 2019, closing a stake of 210,502 shares — an estimated $20.9M sold.

Penn Davis McFarland first reported a position in CELG in Q1 2017 and held it in 11 quarters. The position peaked at $20.9M in Q3 2019. 4 funds tracked by Wall St. Rank hold CELG as of Q4 2019.

  • Penn Davis McFarland reported no remaining Celgene Corp position as of Q4 2019 after selling out during the quarter.
  • Penn Davis McFarland sold 210,502 Celgene Corp shares in Q4 2019, an estimated $20.9M.
  • Penn Davis McFarland first reported a position in Celgene Corp in Q1 2017 and held it in 11 quarters.
  • Penn Davis McFarland's Celgene Corp position peaked at $20.9M in Q3 2019.
  • 4 funds tracked by Wall St. Rank held Celgene Corp as of Q4 2019.

Based on Penn Davis McFarland's 13F filing for Q4 2019, filed 17 Jan 2020.